Autocrine growth factors as therapeutic targets in lung cancer.
Mulshine
J L
JL
NCI-Navy Medical Oncology Branch, National Cancer Institute, Bethesda, Md. 20892.
Treston
A M
AM
Natale
R B
RB
Kasprzyk
P G
PG
Avis
I
I
Nakanishi
Y
Y
Cuttitta
F
F
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001839:Bombesin / Q000037:antagonists & inhibitors; D002986:Clinical Trials as Topic; D004815:Epidermal Growth Factor / Q000037:antagonists & inhibitors; D019886:Gastrin-Releasing Peptide; D006131:Growth Inhibitors / Q000627:therapeutic use*; D006133:Growth Substances; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000037:antagonists & inhibitors; D008175:Lung Neoplasms / Q000628:therapy*; D010455:Peptides / Q000037:antagonists & inhibitors; D014168:Transferrin / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D006131:Growth Inhibitors; D006133:Growth Substances; D010455:Peptides; D014168:Transferrin; D004815:Epidermal Growth Factor; D007334:Insulin-Like Growth Factor I; D019886:Gastrin-Releasing Peptide; D001839:Bombesin